at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Company profile
Ticker
HZNP
Exchange
Website
CEO
Timothy P Walbert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Horizon Pharma plc, HORIZON PHARMA, INC.
SEC CIK
Corporate docs
Subsidiaries
Horizon Medicines LLC • Horizon Therapeutics U.S. Holding LLC • Horizon Properties Holding LLC • Horizon Therapeutics Brasil Ltda • Horizon Therapeutics Capital Limited • Horizon Therapeutics Finance Limited • Horizon Therapeutics Finance • Horizon Therapeutics France SAS • Horizon Therapeutics GmbH • Horizon Therapeutics Holdings Limited ...
IRS number
272179987
HZNP stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
16 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Oct 23
Transcripts
HZNP
Earnings call transcript
2022 Q3
2 Nov 22
HZNP
Earnings call transcript
2022 Q2
3 Aug 22
HZNP
Earnings call transcript
2022 Q1
4 May 22
HZNP
Earnings call transcript
2021 Q4
1 Mar 22
HZNP
Earnings call transcript
2021 Q3
3 Nov 21
HZNP
Earnings call transcript
2021 Q2
4 Aug 21
HZNP
Earnings call transcript
2021 Q1
5 May 21
HZNP
Earnings call transcript
2020 Q4
24 Feb 21
HZNP
Earnings call transcript
2020 Q3
2 Nov 20
HZNP
Earnings call transcript
2020 Q3
2 Nov 20
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
85.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 476 |
Opened positions | 36 |
Closed positions | 73 |
Increased positions | 145 |
Reduced positions | 204 |
13F shares | Current |
---|---|
Total value | 22.34 tn |
Total shares | 195.20 mm |
Total puts | 31.78 mm |
Total calls | 10.77 mm |
Total put/call ratio | 2.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 21.59 mm | $2.50 tn |
Pentwater Capital Management | 15.55 mm | $1.80 tn |
BLK Blackrock | 14.87 mm | $1.72 tn |
Ubs Oconnor | 7.66 mm | $886.68 bn |
Avoro Capital Advisors | 7.00 mm | $809.83 bn |
Farallon Capital Management | 6.66 mm | $770.13 bn |
STT State Street | 5.23 mm | $605.51 bn |
JPM JPMorgan Chase & Co. | 5.04 mm | $583.34 bn |
D. E. Shaw & Co. | 4.72 mm | $545.85 bn |
Millennium Management | 4.59 mm | $530.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Oct 23 | Jeffrey W Sherman | Ordinary Shares | Sale back to company | Dispose D | Yes | No | 116.5 | 45,352 | 5.28 mm | 0 |
6 Oct 23 | Jeffrey W Sherman | Ordinary Shares | Sale back to company | Dispose D | Yes | No | 116.5 | 80,944 | 9.43 mm | 0 |
6 Oct 23 | Jeffrey W Sherman | Ordinary Shares | Sale back to company | Dispose D | Yes | No | 116.5 | 105,808 | 12.33 mm | 0 |
6 Oct 23 | Jeffrey W Sherman | Ordinary Shares | Sale back to company | Dispose D | No | No | 116.5 | 2,655 | 309.31 k | 0 |
6 Oct 23 | Jeffrey W Sherman | RSU Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 9,200 | 0.00 | 0 |
6 Oct 23 | Jeffrey W Sherman | RSU Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 4,599 | 0.00 | 0 |
6 Oct 23 | Jeffrey W Sherman | RSU Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 4,599 | 0.00 | 0 |
6 Oct 23 | Jeffrey W Sherman | RSU Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 19,044 | 0.00 | 0 |
6 Oct 23 | Jeffrey W Sherman | RSU Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 11,426 | 0.00 | 0 |
6 Oct 23 | Jeffrey W Sherman | RSU Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 3,809 | 0.00 | 0 |